← Back to Search
Management Of Platinum-resistant Ovarian Cancer With The Combination Of Pemetrexed And Gemcitabine
J. G. Blesa, V. A. Candel, M. P. Pulla, E. González, S. Algarra
Published 2009 · Medicine
Download PDFAnalyze on Scholarcy
Introduction Platinum resistant ovarian cancer is a current challenge in Oncology. Current approved therapies offer no more of a 20% of response. New therapeutic options are urgently needed.
This paper references
The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
R. Zhao (2000)
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.
B. Lund (1994)
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.
M. Markman (2004)
Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.
A. Adjei (2000)
Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma
M. Galsky (2006)
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
F. Muggia (1997)
What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
E. Han (2007)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
S. Cannistra (2007)
Schedule-Dependent Synergistic Effect of Pemetrexed Combined with Gemcitabine against Malignant Pleural Mesothelioma and Non-Small Cell Lung Cancer Cell Lines
S. Nagai (2008)
A Phase II Trial of 5‐Fluorouracil and High‐Dose Leucovorin in Recurrent Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group Study
K. Y. Look (1995)
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
Cancer Statistics, 2007
A. Jemal (2007)
Pemetrexed in bladder, head and neck, and cervical cancers.
L. Paz-Ares (2002)
A Dose Escalation Study of Gemcitabine plus Pemetrexed Administered Biweekly in Patients with Solid Tumors
A. Kalykaki (2006)
Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
J. L. Tonkinson (1999)
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer.
D. Clarke-Pearson (2001)
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
C. Shih (1997)
Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study.
R. Slayton (1979)
Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
J. Chura (2007)
Bevacizumab combination therapy in recurrent, platinum‐refractory, epithelial ovarian carcinoma
J. Wright (2006)
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
P. Rose (1998)
Synergistic Cytotoxicity and Pharmacogenetics of Gemcitabine and Pemetrexed Combination in Pancreatic Cancer Cell Lines
E. Giovannetti (2004)
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
W. Dean-Colomb (2008)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
R. Burger (2007)
Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.
H. Hochster (1999)
MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma.
B. Teicher (1999)
Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer
G. Rustin (2004)
Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first‐line therapy in patients with advanced nonsmall cell lung carcinoma
F. Shepherd (2001)
Optimal chemotherapy treatment for women with recurrent ovarian cancer
M. Fung-Kee-Fung (2007)
Phase II studies of pemetrexed in metastatic breast and gynecologic cancers.
I. Smith (2004)
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
V. Mey (2006)
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
A. Gordon (2001)
Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report.
M. Markman (1996)
A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.
M. Friedlander (1998)
Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.
P. Sørensen (2001)
Ifosfamide/Mesna as Salvage Therapy in Platinum Pretreated Ovarian Cancer Patients—Long-Term Results of a Phase II Study
M. Baur (2006)
Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
M. Markman (1998)
A phase I study of pemetrexed (P) plus gemcitabine (G) in relapsed ovarian cancer (OC): Dosing results and evidence of activity.
M. Hensley (2006)
Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor–Positive Patients
J. Smyth (2007)
Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases.
F. Lordick (2006)
This paper is referenced by
Whole abdominal radiotherapy in ovarian cancer.
A. Biete (2010)
Emerging role of pemetrexed in ovarian cancer
F. Tomao (2009)
debulked ovarian cancer
Setsuko K. Chambers (2012)
The current state of pemetrexed in ovarian cancer
R. Miller (2013)
Pemetrexed for Ovarian Cancer: A Systematic Review of the Published Literature and a Consecutive Series of Patients Treated in a Nonclinical Trial Setting
Heidi Egloff (2014)
Pemetrexed disodium in ovarian cancer treatment
M. Morotti (2012)